2026-05-16T22:07:41Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/173462024-09-21T22:24:32Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16961
Repisalud author Cassinello, J author Arranz, J Á author Piulats, J M author Sánchez, A author Pérez-Valderrama, B author Mellado, B author Climent, M Á author Olmos, D author Carles, J author Lázaro, M 2024-01-23T20:13:18Z 2024-01-23T20:13:18Z 2017-11-13 10.1007/s12094-017-1783-2 1699-3055 Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico http://hdl.handle.net/10668/11795 29134562 http://hdl.handle.net/20.500.12105/17346 Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma. eng Abiraterone Androgen deprivation treatment Cabazitaxel Castration-resistant prostate cancer Docetaxel Enzalutamide Hormone-sensitive advanced prostate cancer Radium 223 SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). research article